Structure and function of a new class of human prolactin antagonists

Protein Expression and Purification

Volumn 66, Issue 2, 2009, Pages 121-130

  DePalatis, Laura ^a   Almgren, Colleen M ^a   Patmastan, Jypji ^a   Troyer, Mark ^a   Woodrich, Todd ^a   Brooks, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antagonist; Human; Prolactin

Indexed keywords

PROLACTIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; FLOW CYTOMETRY; GENE DELETION; HUMAN; LEUKEMIA CELL LINE; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; PEPTIDE MAPPING; PROTEIN DENATURATION; PROTEIN ENGINEERING; TEMPERATURE;

AMINO ACID SEQUENCE; APOPTOSIS; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; PROLACTIN; PROTEIN DENATURATION; PROTEIN ENGINEERING; SEQUENCE DELETION; TEMPERATURE;

EID: 67349148907     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.02.012     Document Type: Article

References (50)

1. Buhimschi C. Endocrinology of lactation. Obstet. Gynecol. Clin. North Am. 31 (2004) 963-979
2. Krishnan N., Thellin O., Buckley D.J., Horseman N.D., and Buckley A.R. Prolactin suppresses glucocorticoid-induced thymocyte apoptiosis in vivo. Endocrinology 144 (2003) 2102-2110
3. Welsch C.W., and Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 37 (1977) 951-963
4. Welsch C.W. Prolactin and the development and progression of early neoplastic mammary gland lesions. Cancer Res. 38 (1978) 4054-4058
5. Clevenger C.V., Furth P.A., Hankinson S.E., and Schuler L.A. The role of prolactin in mammary carcinoma. Endocr. Rev. 24 (2003) 1-27
6. Ben-Jonathan N., Liby K., McFarland M., and Zinger M. Prolactin as an autocrine/paracrine factor in human cancers. Trends Endocrinol. Metab. 13 (2002) 245-250
7. Goffin V., Bernichtein S., Touraine P., and Kelly P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26 (2005) 400-422
8. Kelly P.A., Ali S., Rozakis M., Goujon L., Nagano M., Pellegrini I., Gould D., Djiane J., Edery M., and Finidori J. The growth hormone/prolactin receptor family. Recent Prog. Horm. Res. 48 (1993) 123-164
9. Boutin J.M., Edery M., Shirota M., Joliceur C., Lesueur L., Ali S., Gould D., Djiane J., and Kelly P.A. Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol. Endocrinol. 3 (1989) 1455-1461
10. Kline J.B., Roehrs H., and Clevenger C.V. Functional characterization of the intermediate isoform of the human prolactin receptor. J. Biol. Chem. 274 (1999) 35461-35468
11. Kline J.B., Rycyzyn M.A., and Clevenger C.V. Characterization of a novel and functional human prolactin receptor isoform (delta S1 PRLr) containing only one extracellular fibronectin-like domain. Mol. Endocrinol. 16 (2002) 2310-2322
12. Kline J.B., and Clevenger C.V. Identification and characterization of the prolactin-binding protein (PRLBP) in human serum and milk. J. Biol. Chem. 276 (2001) 24760-24766
13. Hu Z., Meng J., and Dufau M.L. Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J. Biol. Chem. 276 (2001) 41086-41094
14. Trott J.F., Hovey R.C., Koduri S., and Vonderhaar B.K. Alternative splicing of exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin- binding protein. J. Mol. Endocrinol. 30 (2003) 31-47
15. Trott J.F., Hovey R.C., Koduri S., and Vonderhaar B.K. Multiple new isoforms of the human prolactin receptor gene. Adv. Exptl. Med. Biol. 254 (2004) 495-499
16. Qazi A.M., Tsai-Morris C.-H., and Dufau M.L. Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol. Endocrinol. 20 (2006) 1912-1923
17. Gadd S., and Clevenger C.V. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20 (2006) 2734-2746
18. Sivaprasad U., Canfield J.M., and Brooks C.L. Mechanism of ordered binding by human prolactin. Biochemistry 43 (2004) 13755-13765
19. Duda K.M., and Brooks C.L. Identification of residues outside the two binding sites that are critical for activation of the lactogenic activity of human growth hormone. J. Biol. Chem. 278 (2003) 22734-22739
20. U. Sivaprasad, The mechanism of lactogen receptor binding by human prolactin. Thesis, The Ohio State University Libraries, Call No. THE:BIO2003PHDS582, 2003.
21. Walsh S.T.R., Sylvester J.E., and Kossikoff A.A. The high and low affinity of growth hormone are allosterically coupled. Proc. Natl. Acad. Sci. 101 (2004) 17078-17083
22. Goffin V., Kinet S., Ferrag F., Binart N., Martial J.A., and Kelly P.A. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J. Biol. Chem. 271 (1996) 16573-16579
23. Ramamoorthy P., Sticca R., Wagner T.E., and Chen W.Y. In vitro studies of a prolactin antagonist, hPRL-G129R, in human breast cancer cells. Int. J. Oncol. 18 (2001) 25-32
24. Bernichtein S., Kayser C., Dillner K., Moulin S., Kopchick J.J., Martial J.A., Norstedt G., Isaksson O., Kelly P.A., and Goffin V. Development of pure prolactin receptor antagonists. J. Biol. Chem. 278 (2003) 35988-35999
25. Walker A.M. Therapeutic potential for S179D prolactin-from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin. Invest. Drugs 15 (2006) 1257-1267
26. Chen W.Y., Ramamoorthy P., Chen N.-Y., Sticca R., and Wagner T.E. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 5 (1999) 3583-3593
27. Beck M.T., Pierce S.K., and Chen W.Y. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21 (2002) 5047-5055
28. Pierce S.K., and Chen W.Y. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bxcl-2 gene expression in human cancer cells and transgenic mice. Oncogene 23 (2004) 1248-1255
29. Tomblyn S., Langenheim J.F., Jacquemart I.C., Holle E., and Chen W.Y. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int. J. Oncol. 27 (2005) 381-1389
30. Somers W., Ultsch M., De Vos A.M., and Kossiakoff A.A. The X-ray structure of a growth hormone-prolactin receptor complex. Nature 372 (1994) 478-481
31. Keeler C., Dannies P.S., and Hodsdon M.E. The tertiary structure and backbone dynamics of human prolactin. J. Mol. Biol. 328 (2003) 1105-1121
32. Teilum K., Hoch J.C., Goffin V., Kinet S., Martial J.A., and Kragelund B.B. Solution structure of human prolactin. J. Mol. Biol. 351 (2005) 810-823
33. Jomain J.-B., Tallet E., Broutin I., Hoos S., van Agthoven J., Ducruix A., Kelly P.A., Kragelund B.B., England P., and Goffin V. Structural and thermodynamic bases for the unique properties of del1-9-G129R-hPRL, a pure prolactin receptor antagonist. J. Biol. Chem. 282 (2007) 33118-33131
34. Lewis U.J., Dunn J.T., Bonewald L.F., Seavey B.K., and VanderLaan W.P. A naturally occurring structural variant of human growth hormone. J. Biol. Chem. 253 (1978) 2679-2687
35. DeNoto F.M., Moore D.D., and Goodman H.M. Human growth hormone DNA sequence and mRNA structure: possible alternative splicing. Nucleic Acids Res. 9 (1981) 3719-3730
36. de Vos A.M., Ultsch M., and Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255 (1992) 306-312
37. Chantalat L., Jones N.D., Korber F., Navaza J., and Pavlovsky A.G. The crystal-structure of wild-type growth-hormone at 2.5 Angstrom resolution. Prot. Pep. Lett. 2 (1995) 333-340
38. Tsunekawa B., Wada M., Ikeda M., Uchida H., Naito N., and Honjo M. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Endocrinology 140 (1999) 3909-3918
39. Peterson F.C., and Brooks C.L. Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor. Prot. Eng. Design Sel. 17 (2004) 417-424
40. Peterson F.C., Anderson P.J., Berliner L.J., and Brooks C.L. Expression and folding characterization of small proteins with increasing disulfide complexity by a pT7-7- derived phagemid. Prot. Exp. Purif. 15 (1999) 16-23
41. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
42. G.E. Tarr, Manual Edman sequencing system. In: J.E. Shively (Ed.), Methods of Protein Microcharacterization. Humana Press, Clifton, NJ, 1986, pp. 155-194.
43. Perkins D.N., Pappin D.J.C., Creasy D.M., and Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20 (1999) 3551-3567
44. Chalkley R.J., Baker P.R., Huang L., Hansen K.C., Allen N.P., Rexach M., and Burlingame A.L. Comprehensive analysis of a multidimensional liquid chromatography mass spectrometry dataset acquired on a quadrupole selecting quadrupole collision cell, time- of-flight mass spectrometer. II. New developments in protein prospector allow for reliable and comprehensive automatic analysis of large datasets. Mol. Cell. Proteomics 4 (2005) 1194-1204
45. Kunkel T.A., Bebenek K., and McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Meth. Enzymol. 204 (1991) 125-139
46. J O., Wilson I., T O., and Pognan F. Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267 (2000) 5421-5426
47. Schneider U., Schwenk H., and Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19 (1977) 621-626
48. Matera L., Cutufia M., Geuna M., Contarini M., Buttiglieri S., Galin S., Fazzari A., and Cavaliere C. Prolactin is an autocrine growth factor for jurkat human T-leukemic cell line. J. Neuroimmunol. 79 (1997) 12-21
49. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssiere J.-L., Petit P.X., and Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181 (1995) 1661-1672
50. Castedo M., Ferri K., Roumier T., Metivier D., Zamzami N., and Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J. Immunol. Meth. 265 (2002) 39-47